Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1).
Boris V JanssenStijn van RoesselSusan van DierenOnno de BoerVolkan AdsayOlca BasturkLodewijk BrosensFiona CampbellDeyali ChatterjeeAngela ChouClaudio DoglioniIrene EspositoRoger FeakinsTalia L FuchsNoriyoshi FukushimaAnthony J GillSeung-Mo HongRalph H HrubanJeffrey KaplanAlyssa KrasinkasClaudio LuchiniChanjuan ShiAatur SinghiElizabeth ThompsonMarie-Louise F Van VelthuysenMarc G H BesselinkJoanne VerheijHuamin WangCaroline VerbekeArantza Fariñanull nullPublished in: The British journal of surgery (2022)
Identification of the effect of NAT in resected pancreatic cancer proved unreliable, and interobserver agreement for the current tumour response scoring systems was suboptimal. These findings support the recently published International Study Group of Pancreatic Pathologists recommendations to score residual tumour burden rather than tumour regression after NAT.